Intarcia Therapeutics is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System – medicines that have the potential to transform the prevention and management of serious chronic diseases. The Сompany's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity.
|Size (employees)||325 (est)|
Intarcia Therapeutics total Funding
Intarcia Therapeutics latest funding size
Time since last funding
|2 years ago|
Intarcia Therapeutics investors
|Omega Funds, Kayon Partners, New Enterprise Associates, Alta Partners, New Leaf Venture Partners, The Pritzker Organization, RA Capital Management, The Baupost Group, Venrock, GGV Capital, Quadrille Capital, Marker, Farallon Capital Management, Fidelity Investments, Baillie Gifford, Foresite Capital|
Intarcia Therapeutics has 487 Twitter Followers. The number of followers has increased 0.8% month over month and increased 1.6% quarter over quarter
When was Intarcia Therapeutics founded?
Intarcia Therapeutics was founded in 1997.
Who are Intarcia Therapeutics key executives?
Intarcia Therapeutics's key executives are Kurt Graves, James Ahlers and Thomas Alessi.
How many employees does Intarcia Therapeutics have?
Intarcia Therapeutics has 325 employees.
Who are Intarcia Therapeutics competitors?
Competitors of Intarcia Therapeutics include Sarepta Therapeutics, Zogenix and Merial.
Where is Intarcia Therapeutics headquarters?
Intarcia Therapeutics headquarters is located at 1 Marina Park Drive, Boston.
Where are Intarcia Therapeutics offices?
Intarcia Therapeutics has offices in Durham, Hayward and Boston.
How many offices does Intarcia Therapeutics have?
Intarcia Therapeutics has 3 offices.